The curative effects of simvastatin combined with salmeterol fluticasone in chronic obstructive pulmonary disease treatment
WU Yu-hua
WENG Lin
ZENG Si-wen
CHEN Zuo-ping
XIONG Ai-hua
Abstract：Objective To investigate the effects of simvastatin and salmeterol fluticasone propionate powder inhalation for chronic obstructive pulmonary disease (COPD) on pulmonary function.Methods All 200 cases of COPD were divided into control group (32 cases),simvastatin,inhalation group and combination group,3 groups of 56 patients each.Using quality of life assessment questionnaire (CAT) score,by monitoring of pulmonary function,blood gas analysis and C-reactive protein (CRP) changes,comparison of different treatment methods for 4 sets of COPD change of pulmonary function of patients with COPD.Results The simvastatin group,inhalation group,united group therapy for patients with scores of CAT score [(24 ±4),(24 ±4) and (19 ±3) scores],carbon dioxide partial pressure (PaCO2) [(50 ± 6),(50 ± 6) and (48 ± 6) mm Hg,CRP [(25 ± 9),(26 ± 9) and (18 ±6) mg/L] was significantly lower than that before treatment [CAT score:(27 ±5),(27 ±5) and (27 ±5)scores,PaCO2:(54±8),(54±7) and (54±6) mm Hg,CRP:(39±10),(39±10) and (39±10) mg/L],group differences were statistically significant (P ＜ 0.05).After treatment,the group of patients with CAT score,PaCO2,CRP were lower than those of the simvastatin and inhalation group,the difference between groups was statistically significant (P ＜ 0.05).Simvastatin group,inhalation group,united group patients after forced vital capacity (FVC) [(2.3 ± 0.4),(2.3 ± 0.4) and (2.5 ± 0.5) L],forced expiratory volume in one second (FEV1) [(1.4 ± 0.4),(1.4 ± 0.4) L and (1.7 ± 0.5) L],forced expiratory second rate (FEV1/FVC) [(1.4 ± 0.4),(1.4 ± 0.4) and (1.7 ± 0.5) ％,PaO2 [(68 ± 8),(68 ± 8) and (72 ± 8) mm Hg] were higher than those before treatment [FVC:(2.1± 0.4),(2.1 ±0.4)Land (2.1±0.4) L,FEV1:(1.2±0.3),(1.2±0.3)L and (1.3±0.3) L,FEV1/FVC:(68 ±9),(66±9) and (67±9) ％,PaO2:(63 ±7),(64±8) and (64±8) mm Hg],group differences were statistically significant (P ＜0.05).After treatment,the group of patients with FVC,FEV1,FEV1/FVC,PaO2 higher than that of the simvastatin and inhalation group,the difference between groups was statistically significant (P ＜ 0.05).Conclusion Simvastatin combined with salmeterol fluticasone propionate powder for inhalation therapy can improve pulmonary function,blood gas analysis in patients with COPD.
Keywords：Pulmonary disease,chronic obstructiveSimvastatinSalmeterol fluticasone
Publication Date：2013-05-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 612-614 )